Cardio Diagnostics CEO Outlines India Expansion and Medicare Progress in Podcast Interview
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discusses the company's growth strategy, including expansion into India and progress with Medicare reimbursement, highlighting the importance of precision medicine in cardiovascular disease prevention.
Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to improve cardiovascular disease prevention and early detection through precision medicine, as outlined by CEO and Co-Founder Dr. Meesha Dogan in a recent appearance on The BioMedWire Podcast. Dogan detailed the company's expansion into India via partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as its progress through the Medicare reimbursement process, where CPT coding and payment steps have been completed while coverage determination remains underway.
The company's focus on leveraging epigenetics, genetics, and artificial intelligence positions it at the forefront of personalized cardiovascular care. According to Dogan, the India expansion represents a significant opportunity to address the growing burden of cardiovascular disease in one of the world's most populous countries. By partnering with established healthcare providers like Aimil Ltd. and Dr. Lal PathLabs, Cardio Diagnostics aims to make its proprietary tests accessible to a broader population.
The Medicare reimbursement progress is another critical milestone. With CPT coding and payment steps finalized, the company is closer to securing coverage for its tests, which could substantially expand patient access. The remaining step—coverage determination—will be crucial for widespread adoption. Dogan emphasized that these developments align with the company's goal of making cardiovascular disease prevention more accessible and precise.
Cardio Diagnostics' technology is built on a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to assess cardiovascular risk. This approach moves beyond traditional risk factors, offering a more personalized assessment. The company's tests are designed to detect early signs of disease, potentially preventing heart attacks and strokes.
The implications of this announcement are significant for both the healthcare industry and investors. If Cardio Diagnostics successfully navigates the Medicare process and scales its India operations, it could transform cardiovascular disease management. The company's strategy addresses a major public health need, as cardiovascular diseases remain the leading cause of death globally. By making precision medicine accessible, Cardio Diagnostics could reduce healthcare costs and improve patient outcomes.
Listen to the full episode of The BioMedWire Podcast here for more details. For the latest news and updates on Cardio Diagnostics, visit the company's newsroom at https://ibn.fm/CDIO.